FindTrial
Sign In

Dapagliflozin tablet

DRUG7 trials

Sponsors

Christopher Bell, Peking Union Medical College Hospital, Mansoura University, Centre Hospitalier Universitaire Vaudois, University of Palermo

Conditions

BMDDiabetes Type 2Fontan CirculationHFpEF - Heart Failure With Preserved Ejection FractionHeart FailureHeart Failure AcuteHeart Failure With Preserved Ejection FractionHeart Failure With Reduced Ejection Fraction

Phase 2

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
CompletedNCT03180489
Christopher BellWeight Loss
Start: 2017-05-03End: 2018-12-21Updated: 2020-02-11
Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
Not yet recruitingNCT06012266
Centre Hospitalier Universitaire VaudoisHeart Failure
Start: 2024-08-31End: 2025-08-31Target: 12Updated: 2024-02-07
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
RecruitingNCT06762964
Mayo ClinicFontan Circulation, HFpEF - Heart Failure With Preserved Ejection Fraction, Single Ventricle Heart Disease
Start: 2025-05-16End: 2027-02-28Target: 27Updated: 2025-10-02

Phase 3

A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
RecruitingNCT06589765
Shandong Suncadia Medicine Co., Ltd.Type 2 Diabetes
Start: 2024-09-27End: 2026-07-18Target: 800Updated: 2025-01-09

Phase 4

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
NCT04287387
Peking Union Medical College HospitalType2 Diabetes Mellitus
Start: 2020-03-02End: 2021-03-02Target: 180Updated: 2020-02-27
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
CompletedNCT05704088
Mansoura UniversityBMD, Lupus Nephritis, SGLT2 INHIBITORS
Start: 2022-10-08End: 2024-01-08Updated: 2024-10-15
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Not yet recruitingNCT06442280
University of PalermoDiabetes Type 2, Heart Failure Acute, Heart Failure With Preserved Ejection Fraction +1
Start: 2024-06-30End: 2026-03-30Target: 544Updated: 2024-06-06